Patents Assigned to Stemgen S.P.A.
  • Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPs
    Patent number: 9737589
    Abstract: The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: August 22, 2017
    Assignee: Stemgen S.P.A.
    Inventors: Angelo Luigi Vescovi, Brent Allen Reynolds
  • INHIBITION OF THE TUMORIGENIC POTENTIAL OF TUMOR STEM CELLS BY LIF AND BMPS
    Publication number: 20160228511
    Abstract: The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
    Type: Application
    Filed: November 16, 2015
    Publication date: August 11, 2016
    Applicant: STEMGEN S.P.A.
    Inventors: Angelo Luigi Vescovi, Brent Allen Reynolds
  • Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
    Patent number: 9220756
    Abstract: The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: December 29, 2015
    Assignee: STEMGEN S.P.A.
    Inventors: Angelo Luigi Vescovi, Brent Allen Reynolds
  • Compositions comprising inhibitors of EPH receptor expression in tumor stem cells and methods of treatment thereof
    Patent number: 9078857
    Abstract: The present disclosure concerns the field of malignant tumors of the central nervous system and provides pharmaceutical compositions suitable for the therapeutic and for the prophylactic treatment of brain tumors and for inhibiting the growth of the tumor mass.
    Type: Grant
    Filed: April 18, 2011
    Date of Patent: July 14, 2015
    Assignee: StemGen S.P.A.
    Inventors: Angelo Luigi Vescovi, Elena Binda
  • EPH RECEPTOR EXPRESSION IN TUMOR STEM CELLS
    Publication number: 20120083454
    Abstract: The present disclosure concerns the field of malignant tumors of the central nervous system and provides pharmaceutical compositions suitable for the therapeutic and for the prophylactic treatment of brain tumors and for inhibiting the growth of the tumor mass.
    Type: Application
    Filed: April 18, 2011
    Publication date: April 5, 2012
    Applicant: STEMGEN S.p.A.
    Inventors: Angelo Luigi Vescovi, Elena Binda
  • INHIBITION OF THE TUMORIGENIC POTENTIAL OF TUMOR STEM CELLS BY LIF AND BMPS
    Publication number: 20100167999
    Abstract: The present disclosure includes methods and compositions for the treatment or prevention of diseases and disorders characterized by excessive or misregulated cellular proliferations, including methods for the treatment of tumors. The methods involve the use of pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator. The disclosure also includes LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators, and methods for the identification of LIF preparations, BMP preparations, BMPR signalling activator, and LIFR signalling activators. The disclosure also includes pharmaceutical compositions comprising at least one agent selected from the group consisting of a LIF preparation, a BMP preparation, a BMPR signalling activator, and a LIFR signalling activator.
    Type: Application
    Filed: July 19, 2006
    Publication date: July 1, 2010
    Applicant: Stemgen S.P.A.
    Inventors: Angelo Luigi Vescovi, Brent Allen Reynolds